This review evaluated whether steroid treatment plus antivirals provided a greater degree of facial muscle recovery than steroids alone in patients with Bell's palsy. The authors concluded that combined treatment provided no additional benefit in achieving at least partial facial muscle recovery. This was a generally well-conducted review, and the authors' conclusion is likely to be reliable.
Study selection
Randomised controlled trials (RCTs) with at least one month of follow up after the initiation of treatment, and comparing steroids with combined steroid and antiviral therapy, in patients with Bell's palsy, were eligible for inclusion in the review. Studies of children or pregnant women were excluded, as were those comparing steroids with antivirals alone. The proportion of patients with at least partial facial muscle recovery, assessed using a recognised grading system (such as House-Brackmann, Yanagihara, or the facial paralysis recovery index), was the eligible outcome of interest. The severity of facial muscle paralysis at baseline differed between the included studies, as did the definitions of complete and partial facial muscle recovery. The included steroid was oral prednisone or prednisolone; the included antivirals were acyclovir, valacyclovir, and famcyclovir. A variety of dosing regimens were reported. The authors neither stated how papers were selected from the review, nor how many reviewers performed the selection.
Assessment of study quality
Trial quality was assessed using the Jadad score which evaluates the randomisation process, blinding, and the description of withdrawals or dropouts. Scores were allocated from one (lowest quality) to five (highest quality). Where Jadad scores were equal, the highest ranking was awarded to the larger sample size.
Two independent reviewers assessed trial quality.
Data extraction
Two independent reviewers extracted the data in order to calculate the odds ratios (ORs) and 95% confidence intervals (CIs). Intention-to-treat data were extracted, where possible. Authors were contacted for missing data, where necessary. Disagreements were resolved by a third reviewer.
Methods of synthesis
A random-effects meta-analysis was used to calculate pooled ORs and 95% CIs. Publication bias was assessed using a funnel plot and explored with a trim and fill analysis. Heterogeneity was assessed using the I 2 statistic, and the following sources of potential variation were explored: trial quality, time between symptom onset and treatment (three days or less and over three days), length of follow up (three months or less and over three months), and antiviral type. Sensitivity analysis was performed to assess the inclusion of patients lost to follow up (using a fixed-effect model), and to account for potentially missing studies. Six RCTs (1,145 patients) were included in the meta-analysis. Two trials had a Jadad score of five; one scored four; two scored three, and one scored one. The length of follow up ranged from four months to over 12 months.
Results of the review
A substantial proportion of patients (89.7%) achieved at least partial facial muscle recovery following treatment with steroids or combined therapy. Although combination therapy was favourable, pooled analysis showed that there was no statistically significant difference in the extent of facial muscle recovery when this treatment was compared with steroids alone (odds ratio 1.50; 95% CI: 0.83 to 2.69). This result was unaltered in sensitivity analysis including patients lost to follow up.
Heterogeneity was present (I 2 =47.1%), and an exploration of variables revealed that lower quality studies provided the majority of evidence in favour of combination therapy, but this was not statistically significant. There were no other signficant influences in the exploration of heterogeneity. Publication bias was observed, and the effect of combination therapy was reduced when the trim and fill method was applied.
Authors' conclusions
Combined treatment using steroids and antivirals compared with steroids alone provided no additional benefit in achieving at least partial facial muscle recovery in patients with Bell's palsy.
CRD commentary
This review addressed a clear question, and this was supported by potentially reproducible inclusion criteria. The search strategy included various relevant sources, and attempts were made to minimise any language bias. There was no apparent attempt to locate unpublished material. Publication bias was found to be present, and this was explored by appropriate methods. A relevant validity assessment tool was used to assess the trial quality. Attempts were made in the processes of data extraction and quality assessment to minimise reviewer errors and bias, but it is not clear how the trials were selected beyond the search stage of the review. Adequate study details were provided, and the chosen method of synthesis appears to have been appropriate in the presence of heterogeneity. Variation across the included trials was explored in subgroup analyses and the results of these were used to help interpret the final result. This was a generally well-conducted review, and the authors' conclusion is likely to be reliable.
Implications of the review for practice and research
Practice: The authors stated that the routine addition of antivirals to steroids in treating Bell's palsy was not currently supported.
Research: The authors stated that prospective double-blind studies using modern diagnostic methods (such as polymerase chain reaction for the detection of Herpes virus reactivation) were needed. Trials should use the newer antivirals available (such as valacyclovir or famcyclovir) and assess patients with more severe facial paralysis at baseline.
